Pulse Biosciences Inc. (PLSE)
19.34
0.68 (3.64%)
At close: Jan 28, 2025, 1:59 PM
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences Inc.
| Country | United States |
| IPO Date | May 18, 2016 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Paul Arthur LaViolette |
Contact Details
Address: 3957 Point Eden Way Hayward, California United States | |
| Website | https://www.pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Arthur LaViolette | President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board |
| Darrin R. Uecker | Chief Technology Officer & Director |
| David Danitz | Senior Vice President of Engineering |
| Dr. Richard Nuccitelli Ph.D. | Chief Science Officer |
| Edison Manuel | Vice President of Operations |
| Kenneth B. Stratton Esq., J.D. | General Counsel & Corporate Secretary |
| Kevin P. Danahy | Chief Commercial Officer & Principal Executive Officer |
| Mitchell E. Levinson | Chief Strategy Officer |
| Patty Perla | Vice President of Human Resources |
| Robert W. Duggan | Executive Co-Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 23, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 4 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 4 | Filing |
| Dec 19, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 17, 2024 | 4 | Filing |
| Dec 17, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |